Mutual of America Capital Management LLC Increases Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Mutual of America Capital Management LLC lifted its position in Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Rating) by 5.5% in the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 9,754 shares of the medical equipment provider’s stock after purchasing an additional 505 shares during the period. Mutual of America Capital Management LLC’s holdings in Lantheus were worth $539,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the company. Maryland State Retirement & Pension System boosted its holdings in shares of Lantheus by 1.5% in the fourth quarter. Maryland State Retirement & Pension System now owns 26,986 shares of the medical equipment provider’s stock valued at $780,000 after purchasing an additional 386 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Lantheus by 9.2% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,649 shares of the medical equipment provider’s stock valued at $534,000 after purchasing an additional 814 shares during the period. Advisor Group Holdings Inc. boosted its holdings in shares of Lantheus by 6.2% in the fourth quarter. Advisor Group Holdings Inc. now owns 17,576 shares of the medical equipment provider’s stock valued at $507,000 after purchasing an additional 1,031 shares during the period. Public Sector Pension Investment Board boosted its holdings in shares of Lantheus by 0.9% in the fourth quarter. Public Sector Pension Investment Board now owns 137,875 shares of the medical equipment provider’s stock valued at $3,983,000 after purchasing an additional 1,270 shares during the period. Finally, Loomis Sayles & Co. L P boosted its holdings in shares of Lantheus by 0.3% in the fourth quarter. Loomis Sayles & Co. L P now owns 406,612 shares of the medical equipment provider’s stock valued at $11,747,000 after purchasing an additional 1,320 shares during the period. Hedge funds and other institutional investors own 97.14% of the company’s stock.

Lantheus Stock Performance

Shares of LNTH stock opened at $76.72 on Friday. The business’s fifty day simple moving average is $66.94 and its 200-day simple moving average is $54.08. The company has a market cap of $5.27 billion, a PE ratio of -134.60 and a beta of 0.75. The company has a current ratio of 1.83, a quick ratio of 1.64 and a debt-to-equity ratio of 0.31. Lantheus Holdings, Inc. has a 12-month low of $22.20 and a 12-month high of $78.17.

Lantheus (NASDAQ:LNTH – Get Rating) last released its earnings results on Friday, April 29th. The medical equipment provider reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.56. Lantheus had a positive return on equity of 19.83% and a negative net margin of 6.89%. The firm had revenue of $208.90 million for the quarter, compared to the consensus estimate of $165.30 million. During the same period in the prior year, the firm earned $0.05 EPS. The firm’s revenue was up 125.8% on a year-over-year basis. Analysts expect that Lantheus Holdings, Inc. will post 2.84 earnings per share for the current fiscal year.

Insider Activity at Lantheus

In other Lantheus news, CAO Andrea Sabens sold 1,093 shares of the company’s stock in a transaction on Monday, July 18th. The shares were sold at an average price of $71.47, for a total value of $78,116.71. Following the sale, the chief accounting officer now directly owns 63,162 shares of the company’s stock, valued at $4,514,188.14. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Lantheus news, CAO Andrea Sabens sold 1,093 shares of the company’s stock in a transaction on Monday, July 18th. The shares were sold at an average price of $71.47, for a total value of $78,116.71. Following the sale, the chief accounting officer now directly owns 63,162 shares of the company’s stock, valued at $4,514,188.14. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Daniel Niedzwiecki sold 1,380 shares of the company’s stock in a transaction on Wednesday, May 18th. The shares were sold at an average price of $64.54, for a total transaction of $89,065.20. Following the completion of the sale, the insider now directly owns 71,143 shares in the company, valued at $4,591,569.22. The disclosure for this sale can be found here. Insiders have sold a total of 26,798 shares of company stock valued at $1,676,307 in the last ninety days. Company insiders own 1.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on LNTH shares. B. Riley started coverage on shares of Lantheus in a research note on Monday, May 9th. They issued a “buy” rating and a $91.00 price objective for the company. Truist Financial boosted their price objective on shares of Lantheus from $77.00 to $94.00 in a research note on Monday, May 2nd. Finally, SVB Leerink reissued an “outperform” rating and issued a $100.00 price objective on shares of Lantheus in a research note on Monday, June 6th.

Lantheus Company Profile

(Get Rating)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors.